XNAS
STOK
Market cap1.57bUSD
Oct 08, Last price
23.95USD
1D
-1.40%
1Q
-23.68%
IPO
-7.88%
Name
Stoke Therapeutics Inc
Chart & performance
P/E
—
P/S
8.38
EPS
—
Div yield, %
—
Shrs. gr., 5y
12.08%
Rev. gr., 5y
%
Revenues
184m
+404.50%
Net income
-7m
L-92.26%
CFO
46m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Key people
Chief Executive Officer, Principal Executive Officer, Director · since 2025
Thomas Leggett
Chief Financial Officer · since 2024
Barry Ticho
Chief Medical Officer · since 2017
Jonathan Allan
General Counsel, Corporate Secretary · since 2022
Director · since 2025
Independent Director · since 2019
Seth Harrison
Independent Director · since 2025
Adrian Krainer
Independent Director · since 2014
Arthur Levin
Independent Director · since 2015
Independent Director · since 2020
Julie Smith
Independent Director · since 2020
Independent Chairman of the Board · since 2025
IPO date
Jun 19, 2019
Employees
117
Domiciled in
US
Incorporated in
US
Legal address
C/O INCORPORATING SERVICES, LTD.
3500 S DUPONT HWY
DOVER, DE 19901
US
3500 S DUPONT HWY
DOVER, DE 19901
US
Headquarters
45 Wiggins Avenue
Bedford, MA 01730
US
Bedford, MA 01730
US
Previous name
ASOTHERA PHARMAECUTICALS, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||